Skip to main content

Table 1 Baseline characteristics of study participants

From: Epidemiologic and viral predictors of antiretroviral drug resistance among persons living with HIV in a large treatment program in Nigeria

Patient characteristics

All patients

n = 458

Without ADR

N = 299

With ADR

N = 159

P-valuea

Socio-demographics

 Age (years), mean (SD)

34.7 (9.0)

34.3 (9.0)

35.5 (9.0)

0.08

 Age categories (years) (%)

  17–30

163 (35.6%)

116 (38.8%)

47 (29.6%)

0.15

  31–40

181 (39.5%)

112 (37.5%)

69 (43.4%)

  41 and above

114 (25.9%)

71 (23.8%)

43 (27.0%)

 Gender, female (%)

298 (65.1%)

200 (66.9%)

98 (61.6%)

0.26

 Married status, married (%)

239 (52.9%)

177 (60.4%)

62 (39.0%)

< 0.001

 Occupation (%)

  Unemployed

204 (44.5%)

141 (47.2%)

63 (39.6%)

0.038

  Employed

254 (55.4%)

158 (52.8%)

96 (60.3%)

 Education (%)

  None

108 (23.6%)

80 (26.8%)

28 (17.6%)

0.002

  Primary

67 (14.6%)

53 (17.7%)

14 (8.8%)

  Secondary

158 (34.5%)

93 (31.1%)

65 (40.9%)

  Tertiary

125 (27.3%)

73 (24.4%)

52 (32.7%)

Clinical

 Year of enrolment (%)

  2004–2006

222 (58.9%)

125 (48.5%)

97 (80.2%)

< 0.001

  2007–2011

157 (41.4%)

133 (51.6%)

24 (19.8%)

 ART treatment duration (years), mean (SD)

2.9 (1.2)

2.6 (1.1)

3.5 (1.3)

< 0.001

 Baseline CD4 count (cells/µl), mean (SD)

160 (88)

161 (91)

159 (81)

0.98

 Baseline CD4 count < 200 cells/µl (%)

277 (61.8%)

188 (62.9%)

89 (59.7%)

0.52

 CD4 count at ADR (cells/µl), mean (SD)

317 (144)

390 (111)

170 (72)

< 0.001

 CD4 count at ADR < 200 cells/µl (%)

109 (24.3%)

7 (2.3%)

102 (68.5%)

< 0.001

 Baseline viral load log 10, mean (SD)

4.46 (1.00)

4.24 (1.02)

4.87 (0.84)

< 0.001

 Previous ARV regimen (%)

  NNRTI

422 (92.1%)

278 (93.0%)

144 (90.6%)

0.36

  PI

36 (7.9%)

21 (7.0%)

15 (9.4%)

 Non-adherence to care (%)

183 (40.0%)

87 (29.1%)

96 (60.4%)

< 0.001

 Hepatitis B status (%)

97 (20.2%)

59 (19.7%)

38 (23.9%)

0.30

  1. NNRTI non-nucleoside reverse transcriptase inhibitors, PI protease inhibitors, ADR adverse drug reaction, ART ARV therapy, ARV antiretroviral
  2. aP-values from Chi squared-test for categorical variables or Wilcoxon test for continuous variables